These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28675676)

  • 1. Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants.
    Chandran S; Tang Q; Sarwal M; Laszik ZG; Putnam AL; Lee K; Leung J; Nguyen V; Sigdel T; Tavares EC; Yang JYC; Hellerstein M; Fitch M; Bluestone JA; Vincenti F
    Am J Transplant; 2017 Nov; 17(11):2945-2954. PubMed ID: 28675676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
    Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
    Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation.
    Seifert ME; Yanik MV; Feig DI; Hauptfeld-Dolejsek V; Mroczek-Musulman EC; Kelly DR; Rosenblum F; Mannon RB
    Am J Transplant; 2018 Sep; 18(9):2189-2199. PubMed ID: 29766640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
    Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
    Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.
    Jordan SC; Choi J; Aubert O; Haas M; Loupy A; Huang E; Peng A; Kim I; Louie S; Ammerman N; Najjar R; Puliyanda D; Vo A
    Am J Transplant; 2018 Dec; 18(12):2955-2964. PubMed ID: 29637714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants.
    Mathew JM; H-Voss J; LeFever A; Konieczna I; Stratton C; He J; Huang X; Gallon L; Skaro A; Ansari MJ; Leventhal JR
    Sci Rep; 2018 May; 8(1):7428. PubMed ID: 29743501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
    Luque S; Lúcia M; Melilli E; Lefaucheur C; Crespo M; Loupy A; Bernal-Casas D; Gomà M; Jarque M; Crespo E; Montero N; Manonelles A; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
    Am J Transplant; 2019 Feb; 19(2):368-380. PubMed ID: 30085394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.
    Lefaucheur C; Gosset C; Rabant M; Viglietti D; Verine J; Aubert O; Louis K; Glotz D; Legendre C; Duong Van Huyen JP; Loupy A
    Am J Transplant; 2018 Feb; 18(2):377-390. PubMed ID: 29086461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon Gamma ELISPOT Testing as a Risk-Stratifying Biomarker for Kidney Transplant Injury: Results From the CTOT-01 Multicenter Study.
    Hricik DE; Augustine J; Nickerson P; Formica RN; Poggio ED; Rush D; Newell KA; Goebel J; Gibson IW; Fairchild RL; Spain K; Iklé D; Bridges ND; Heeger PS;
    Am J Transplant; 2015 Dec; 15(12):3166-73. PubMed ID: 26226830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function.
    Guillén-Gómez E; Dasilva I; Silva I; Arce Y; Facundo C; Ars E; Breda A; Ortiz A; Guirado L; Ballarín JA; Díaz-Encarnación MM
    Am J Transplant; 2017 Mar; 17(3):733-743. PubMed ID: 27496082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex Vivo Costimulatory Blockade to Generate Regulatory T Cells From Patients Awaiting Kidney Transplantation.
    Guinan EC; Cole GA; Wylie WH; Kelner RH; Janec KJ; Yuan H; Oppatt J; Brennan LL; Turka LA; Markmann J
    Am J Transplant; 2016 Jul; 16(7):2187-95. PubMed ID: 26790369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of regulatory T cells on short-term graft outcome in kidney transplant recipients, a prospective observational, single-center study.
    Bejugama K; Taduri G; Guditi S
    Transpl Immunol; 2022 Aug; 73():101630. PubMed ID: 35643376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.
    Kulkarni S; Kirkiles-Smith NC; Deng YH; Formica RN; Moeckel G; Broecker V; Bow L; Tomlin R; Pober JS
    Am J Transplant; 2017 Mar; 17(3):682-691. PubMed ID: 27501352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients.
    Harden PN; Game DS; Sawitzki B; Van der Net JB; Hester J; Bushell A; Issa F; Brook MO; Alzhrani A; Schlickeiser S; Scotta C; Petchey W; Streitz M; Blancho G; Tang Q; Markmann J; Lechler RI; Roberts ISD; Friend PJ; Hilton R; Geissler EK; Wood KJ; Lombardi G
    Am J Transplant; 2021 Apr; 21(4):1603-1611. PubMed ID: 33171020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonchimeric HLA-Identical Renal Transplant Tolerance: Regulatory Immunophenotypic/Genomic Biomarkers.
    Leventhal JR; Mathew JM; Salomon DR; Kurian SM; Friedewald JJ; Gallon L; Konieczna I; Tambur AR; Charette J; Levitsky J; Jie C; Kanwar YS; Abecassis MM; Miller J
    Am J Transplant; 2016 Jan; 16(1):221-34. PubMed ID: 26227106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyalinosis Lesions in Renal Transplant Biopsies: Time-Dependent Complexity of Interpretation.
    Einecke G; Reeve J; Halloran PF
    Am J Transplant; 2017 May; 17(5):1346-1357. PubMed ID: 27873464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
    Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
    Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and pathological significance of borderline T cell-mediated rejection.
    Nankivell BJ; Agrawal N; Sharma A; Taverniti A; P'Ng CH; Shingde M; Wong G; Chapman JR
    Am J Transplant; 2019 May; 19(5):1452-1463. PubMed ID: 30501008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol.
    Mehta R; Bhusal S; Randhawa P; Sood P; Cherukuri A; Wu C; Puttarajappa C; Hoffman W; Shah N; Mangiola M; Zeevi A; Tevar AD; Hariharan S
    Am J Transplant; 2018 Jul; 18(7):1710-1717. PubMed ID: 29247472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.